NeoGenomics, Inc. (NGNM.OB) Reports Record Quarterly Revenue of $15.7 Million, Adjusted EBITDA of $1.8 Million and 46.3% Gross Margin for the First Quarter
4/25/2013 7:52:03 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
FT. MYERS, Fla., April 25, 2013 -- /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the first quarter of 2013.
First Quarter 2013 Highlights:
Test Volume Growth of 19%
Help employers find you! Check out all the jobs and post your resume.